Whereas hypersialylation of the surface of cancer cells is often attributed to sialyltransferase upregulation, downregulation of neuraminidase (NEU) enzymes, which thereby prevents the cleavage of sialic acids from cell-surface glycoconjugates, also gives rise to increased sialylation. This evidence concerns the gene ERBB2 and cancer.